Key TakeawaysEli Lilly will acquire Verve for roughly $1 billionVerve is developing a one-time gene-editing treatment for ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...